Increasing Incidence of Multiply Recurrent Clostridium difficile Infection in the United States: A Cohort Study
- PMID: 28672282
- DOI: 10.7326/M16-2733
Increasing Incidence of Multiply Recurrent Clostridium difficile Infection in the United States: A Cohort Study
Abstract
Background: Clostridium difficile infection (CDI), the most common health care-associated infection, often recurs. Fecal microbiota transplantation is increasingly used to treat multiply recurrent CDI (mrCDI).
Objective: To determine whether the incidence of mrCDI is increasing in proportion to CDI and to identify risk factors for mrCDI.
Design: Retrospective cohort study.
Setting: United States.
Participants: 38 911 718 commercially insured patients in the OptumInsight Clinformatics Database, of whom 45 341 developed CDI.
Measurements: Age- and sex-standardized incidence rates for CDI and mrCDI.
Results: From 2001 to 2012, the annual incidence of CDI and mrCDI per 1000 person-years increased by 42.7% (from 0.4408 to 0.6289 case) and 188.8% (from 0.0107 to 0.0309 case), respectively. The increase in mrCDI incidence was independent of known risk factors for CDI. Those who developed mrCDI were older (median age, 56.0 vs. 49.0 years; adjusted odds ratio [aOR] per 10-year increase in age, 1.25 [95% CI, 1.21 to 1.29]) and were more likely to be female (63.8% vs. 58.7%; aOR, 1.24 [CI, 1.11 to 1.38]) and to have used antibiotics (72.3% vs. 58.8%; aOR, 1.79 [CI, 1.59 to 2.01]), proton-pump inhibitors (24.6% vs. 18.2%; aOR, 1.14 [CI, 1.01 to 1.29]), or corticosteroids (18.3% vs. 13.7%; aOR, 1.15 [CI, 1.00 to 1.32]) within 90 days of CDI diagnosis. Chronic kidney disease (10.4% vs. 5.6%; aOR, 1.49 [CI, 1.24 to 1.80]) and diagnosis in a nursing home (2.1% vs. 0.6%; aOR, 1.99 [CI, 1.34 to 2.93]) were also associated with increased risk for mrCDI.
Limitation: The primary analyses included only commercially insured patients in the United States.
Conclusion: Relative to CDI, mrCDI incidence has disproportionately increased, indicating a rising demand for mrCDI therapies.
Primary funding source: National Institute of Diabetes and Digestive and Kidney Diseases and National Institute of Allergy and Infectious Diseases.
Comment in
-
Fool Me Thrice: The Evolving Story of Multiply Recurrent Clostridium difficile Infection.Ann Intern Med. 2017 Aug 1;167(3):202-203. doi: 10.7326/M17-1565. Epub 2017 Jul 4. Ann Intern Med. 2017. PMID: 28672286 No abstract available.
-
Increasing Incidence of Multiply Recurrent Clostridium difficile Infection.Ann Intern Med. 2018 Feb 20;168(4):307. doi: 10.7326/L17-0600. Ann Intern Med. 2018. PMID: 29459963 No abstract available.
-
Increasing Incidence of Multiply Recurrent Clostridium difficile Infection.Ann Intern Med. 2018 Feb 20;168(4):307-308. doi: 10.7326/L17-0601. Ann Intern Med. 2018. PMID: 29459964 No abstract available.
-
Increasing Incidence of Multiply Recurrent Clostridium difficile Infection.Ann Intern Med. 2018 Feb 20;168(4):308. doi: 10.7326/L17-0602. Ann Intern Med. 2018. PMID: 29459965 No abstract available.
Similar articles
-
Long-term Outcomes Following Multiply Recurrent Clostridioides difficile Infection and Fecal Microbiota Transplantation.Clin Gastroenterol Hepatol. 2022 Apr;20(4):806-816.e6. doi: 10.1016/j.cgh.2020.12.004. Epub 2020 Dec 8. Clin Gastroenterol Hepatol. 2022. PMID: 33307184 Free PMC article.
-
Fecal microbiota transplantation and Clostridioides difficile infection among privately insured patients in the United States.J Gastroenterol. 2022 Jan;57(1):10-18. doi: 10.1007/s00535-021-01822-y. Epub 2021 Sep 8. J Gastroenterol. 2022. PMID: 34495400
-
Clostridium difficile in a HIV-infected cohort: incidence, risk factors, and clinical outcomes.AIDS. 2013 Nov 13;27(17):2799-807. doi: 10.1097/01.aids.0000432450.37863.e9. AIDS. 2013. PMID: 23842125 Free PMC article.
-
Clostridioides difficile infection: a comprehensive review for primary providers.Rom J Intern Med. 2021 Aug 26;59(3):262-269. doi: 10.2478/rjim-2021-0010. Print 2021 Sep 1. Rom J Intern Med. 2021. PMID: 33713592 Review.
-
Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!J Intern Med. 2021 Aug;290(2):294-309. doi: 10.1111/joim.13290. Epub 2021 Apr 15. J Intern Med. 2021. PMID: 33856727 Review.
Cited by
-
Clostridioides difficile and Gut Microbiota: From Colonization to Infection and Treatment.Pathogens. 2024 Jul 31;13(8):646. doi: 10.3390/pathogens13080646. Pathogens. 2024. PMID: 39204246 Free PMC article. Review.
-
Patient Factors Associated With Gastroesophageal Reflux Disease Diagnostic Evaluation Strategies: A Retrospective Cohort Study Using Real-World Evidence From a Large U.S. Medical Claims Database.Gastro Hep Adv. 2022 May 6;1(4):563-572. doi: 10.1016/j.gastha.2022.03.001. eCollection 2022. Gastro Hep Adv. 2022. PMID: 39132063 Free PMC article.
-
Fecal microbiota transplantation: current challenges and future landscapes.Clin Microbiol Rev. 2024 Jun 13;37(2):e0006022. doi: 10.1128/cmr.00060-22. Epub 2024 May 8. Clin Microbiol Rev. 2024. PMID: 38717124 Review.
-
Characteristics of Patients With Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences.Open Forum Infect Dis. 2024 Mar 6;11(4):ofae127. doi: 10.1093/ofid/ofae127. eCollection 2024 Apr. Open Forum Infect Dis. 2024. PMID: 38577028 Free PMC article.
-
Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infection.Therap Adv Gastroenterol. 2024 Mar 24;17:17562848241239547. doi: 10.1177/17562848241239547. eCollection 2024. Therap Adv Gastroenterol. 2024. PMID: 38529070 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources